Opinion and Evidence for Treatments in Endocrine Disorders
- PDF / 117,849 Bytes
- 10 Pages / 609.45 x 790.87 pts Page_size
- 85 Downloads / 164 Views
Treat Endocrinol 2002; 1 (5): 337-346 1175-6349/02/0005-0337/$25.00/0 © Adis International Limited. All rights reserved.
Opinion and Evidence for Treatments in Endocrine Disorders Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Combined Hormone Replacement Therapy: Increased Breast Cancer Risk, Lack of Benefit . . . . . . . . . 2. Long-Term Hormone Replacement Therapy: No Overall Benefit for Coronary Heart Disease . . . . . . . . . 3. Endometrial Safety of Continuous Combined Hormone Replacement Therapy . . . . . . . . . . . . . . . . . 4. Estrogen-Only Hormone Replacement Therapy Increases Risk of Ovarian Cancer . . . . . . . . . . . . . . . 5. Hormone Replacement Therapy Improves Postmenopausal Chromium Status . . . . . . . . . . . . . . . . . 6. Somatropin Increases Cancer Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7. Long-Term Somatropin: Benefit in Idiopathic Isolated Growth Hormone Deficiency? . . . . . . . . . . . . . . 8. Caffeine/Ephedrine Promotes Bodyweight Loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9. S-12911: ‘Promising’ in Postmenopausal Osteoporosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10. Diabetes Mellitus: Individually Tailored Targets Required . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11. No increased Risk of Diabetes Mellitus with Clozapine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12. Olanzapine Increases Risk of Diabetes Mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13. Thiazolidinediones in the Insulin Resistance Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14. Insulin Aspart/Insulin Protamine Aspart Improves Postprandial Glycemic Control . . . . . . . . . . . . . . . . 15. Transdermal Androstanolone: Useful Alternative For Male Hormone Replacement Therapy? . . . . . . . . . 16. Options For Infertility Treatment Reviewed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17. Raloxifene Enhances Postmenopausal Ovarian Circulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18. Octreotide Detrimental to Glucose Metabolism in Acromegaly . . . . . . . . . . . . . . . . . . . . . . . . . . 19. Gastroduodenal Safety of Alendronate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20. Naltrexone: Endocrine Effects in Polycystic Ovary Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21. No Increased Risk of Breast Cancer with Oral Contraceptives . . . . . . . . . . . . . . . . . . . . . . . . . . . 22. Oral Contraceptives Associated with Low Glucose Levels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23. Does Current Methodology Overestimate the Risk of Venous Thromboembolism with Oral Contraceptives?
Abstract
. . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . .
. . . .
Data Loading...
